Using conventional drug discovery and novel synthetic biology approaches, some investigators and companies are mining our resident microbes and their metabolites for targets in small-molecule drug programs. Ken Garber reports.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Dysbiotic drift and biopsychosocial medicine: how the microbiome links personal, public and planetary health
BioPsychoSocial Medicine Open Access 03 May 2018
-
The Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for Stroke
Neurotherapeutics Open Access 06 October 2016
-
Dysbiotic drift: mental health, environmental grey space, and microbiota
Journal of Physiological Anthropology Open Access 07 May 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
12 October 2016
In the version of this article initially published, on p.231, left-hand column, the maker of linaclotide was said to be Redwood rather than Ironwood Pharmaceuticals. In addition, linaclotide is no longer referred to as a “homolog of the enterotoxin peptides,” but as “similar to the enterotoxin peptides,” and it has been clarified to be “rationally designed.” The errors have been corrected in the HTML and PDF versions of the article.
References
Wang, Z. et al. Nature 472, 57–63 (2011).
van Nood, E. et al. N. Engl. J. Med. 368, 407–415 (2013).
Hsiao, E.Y. et al. Cell 155, 1451–1463 (2013).
Mazmanian, S.K. et al. Cell 122, 107–118 (2005).
Atarashi, K. et al. Nature 500, 232–236 (2013).
Trompette, A. et al. Nat. Med. 20, 159–166 (2014).
Chang, P.V. et al. Proc. Natl. Acad. Sci. USA 111, 2247–2252 (2014).
Yoshimoto, S. et al. Nature 499, 97–101 (2013).
Donia, M.S. et al. Cell 158, 1402–1414 (2014).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Drugging the gut microbiome. Nat Biotechnol 33, 228–231 (2015). https://doi.org/10.1038/nbt.3161
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3161
This article is cited by
-
Modelling host–microbiome interactions in organ-on-a-chip platforms
Nature Reviews Bioengineering (2023)
-
Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases
Digestive Diseases and Sciences (2020)
-
Dysbiotic drift and biopsychosocial medicine: how the microbiome links personal, public and planetary health
BioPsychoSocial Medicine (2018)
-
Erratum: Drugging the gut microbiome
Nature Biotechnology (2017)
-
The Gut Microbiome as Therapeutic Target in Central Nervous System Diseases: Implications for Stroke
Neurotherapeutics (2016)
